3 unchanged sentences
CONSOLIDATED CONDENSED BALANCE SHEETS AS OF
−Removed: MARCH 31, 2026 AND DECEMBER 31, 2025
+Added: JUNE 30, 2026 AND DECEMBER 31, 2025
(in thousands)
−Removed: MARCH 31, 2026
+Added: JUNE 30, 2026
DECEMBER 31, 2025
12 unchanged sentences
Accrued expenses
−Removed: Current portion of notes payable
Total current liabilities
−Removed: Notes payable
Deferred tax liability - Femcare IIA
−Removed: Other long term liabilities
Long-term lease liability
4 unchanged sentences
authorized - 50,000 shares;
−Removed: issued and outstanding - March 31, 2026, 3,184 shares and December 31, 2025, 3,186 shares
+Added: issued and outstanding - June 30, 2026, 3,183 shares and December 31, 2025, 3,186 shares
Accumulated other comprehensive loss
6 unchanged sentences
AND SUBSIDIARIES
−Removed: CONSOLIDATED CONDENSED STATEMENTS OF INCOME
−Removed: FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND MARCH 31, 2025
−Removed: (in thousands, except per share amounts)
+Added: CONSOLIDATED CONDENSED STATEMENTS OF INCOME FOR THE
+Added: THREE AND SIX MONTHS ENDED JUNE 30, 2026 AND JUNE 30, 2025
+Added: (in thousands, except per share amounts - unaudited)
Three Months Ended
+Added: Six Months Ended
Cost of goods sold
11 unchanged sentences
Other comprehensive income (loss):
−Removed: Foreign currency translation net of taxes of
−Removed: $ 0 in all periods
+Added: Foreign currency translation net of taxes of $ 0 in all periods
Total comprehensive income
3 unchanged sentences
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
−Removed: FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND MARCH 31, 2025
+Added: FOR THE SIX MONTHS ENDED JUNE 30, 2026 AND JUNE 30, 2025
(in thousands - unaudited)
+Added: Six Months Ended
CASH FLOWS FROM OPERATING ACTIVITIES:
1 unchanged sentence
cash provided by operating activities
−Removed: Provision for losses on/(recovery of) accounts receivable
+Added: Provision for (recovery of) losses on accounts receivable
Amortization of Right-of-Use Assets
1 unchanged sentence
Stock-based compensation expense
+Added: Tax benefit attributable to exercise of stock options
Changes in operating assets and liabilities:
8 unchanged sentences
Property and equipment
−Removed: Net cash provided by/(used in) investing activities
+Added: Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
3 unchanged sentences
Effect of exchange rate changes on cash
−Removed: Net increase in cash and cash equivalents
+Added: Net increase/(decrease) in cash and cash equivalents
Cash at beginning of period
5 unchanged sentences
UTAH MEDICAL PRODUCTS, INC.
−Removed: AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY
−Removed: Three Months Ended March 31, 2026 and 2025
+Added: Three Months and Six Months Ended June 30, 2026 and 2025
(In thousands - unaudited)
7 unchanged sentences
Balance at March 31, 2026
+Added: Stock option compensation expense
+Added: Common stock purchased and retired
+Added: Foreign currency translation adjustment
+Added: Common stock dividends
+Added: Balance at June 30, 2026
Balance at December 31, 2024
+Added: Shares issued upon exercise of employee
+Added: stock options for cash
Stock option compensation expense
3 unchanged sentences
Balance at March 31, 2025
+Added: Shares issued upon exercise of employee
+Added: stock options for cash
+Added: Stock option compensation expense
+Added: Common stock purchased and retired
+Added: Foreign currency translation adjustment
+Added: Common stock dividends
+Added: Balance at June 30, 2025
+Added: see notes to consolidated condensed financial statements
UTAH MEDICAL PRODUCTS, INC.
16 unchanged sentences
The Company is evaluating the impact of adopting ASU 2025-06.
−Removed: (3) Inventories at March 31, 2026 and December 31, 2025 consisted of the following:
+Added: (3) Inventories at June 30, 2026 and December 31, 2025 consisted of the following:
Finished goods
2 unchanged sentences
(4) Stock-Based Compensation.
−Removed: At March 31, 2026, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors.
+Added: At June 30, 2026, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors.
The Company accounts for stock compensation under FASB Accounting Standards Codification (“ASC”) 718, Compensation - Stock Compensation .
This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors.
−Removed: In the quarters ended March 31, 2026 and March 31, 2025, the Company recognized $ 120 and $ 82 , respectively, in stock-based compensation cost.
+Added: In the six months ended June 30, 2026 and June 30, 2025, the Company recognized $ 192 and $ 168 , respectively, in stock-based compensation cost.
(5) Warranty Reserve.
4 unchanged sentences
The amount of this reserve is adjusted, as required, to reflect its actual experience.
−Removed: Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2025 or March 31, 2026.
+Added: Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2025 or June 30, 2026.
(6) 2Q 2026 global revenues (USD) by product category:
1 unchanged sentence
Blood Pressure Monitoring and Accessories
+Added: Global 1H 2026 revenues (USD) by product category:
+Added: Gynecology/Electrosurgery/Urology
+Added: Blood Pressure Monitoring and Accessories
7) Earnings Per Share.
Basic earnings per share were calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during each applicable period.
−Removed: Diluted earnings per share were calculated by assuming the exercise of stock options at the closing price of stock at the end of first quarter 2026 and 2025, as applicable.
+Added: Diluted earnings per share were calculated by assuming the exercise of stock options at the closing price of stock at the end of 2Q 2026 and 2025, as applicable.
The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:
−Removed: Three months ended March 31
(in thousands)
+Added: Three months ended
+Added: Six months ended
Weighted average shares, basic
8 unchanged sentences
These financial metrics are used by the CODM to make key operating decisions such as the allocation of budget between cost of sales, sales and marketing, research and development, and general and administrative expenses.
−Removed: The following table presents selected financial information with respect to the Company’s single operating segment for the quarters ended March 31, 2026 and March 31, 2025:
−Removed: Quarter Ended March 31,
+Added: The following table presents selected financial information with respect to the Company’s single operating segment for the quarters ended June 30, 2026 and June 30, 2025:
+Added: Quarter Ended June 30,
Standard cost of sales
12 unchanged sentences
(9) Subsequent Events.
−Removed: UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its March 31, 2026 financial statements.
+Added: UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its June 30, 2026 financial statements.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.